Maha H. Hussain, MD, FACP, FASCO, Author at Grand Rounds in Urology

Maha H. Hussain, MD, FACP, FASCO

Northwestern University

Chicago, Illinois

Maha H. Hussain, MD, is the Genevieve Teuton Professor of Medicine in the Division of Hematology-Oncology of the Department of Medicine at Northwestern University Feinberg School of Medicine in Chicago. She is also Deputy Director of the Robert H. Lurie Comprehensive Cancer Center. In this role, Hussain plays a critical role in establishing the overall strategic direction, policy and priorities of the Lurie Cancer Center.. She is also a practicing oncologist and clinical researcher. Dr. Hussain’s research efforts are focused on the development of novel therapeutics integrating scientific advances into clinical trials for prostate and bladder cancer. Her extensive national scientific leadership roles include serving as Co-Chair of the Prostate Cancer Subcommittee/Genitourinary Cancer Committee of SWOG, where she guided research in areas of advanced prostate cancer that led to changing standards of care. Among other positions, she has served as a member and Chair of the Integration Panel of the U.S. Army Medical Research and Materiel Command Prostate Cancer Research Program and as a member and Chair of the U.S. Food and Drug Administration Oncology Drug Advisory Committee. Prior to joining the Lurie Cancer Center in September 2016, she was Associate Director for Clinical Research at the University of Michigan Cancer Center.

Disclosures:

Talks by Maha H. Hussain, MD, FACP, FASCO

PROfound Trial Shows Increased rPFS in mCRPC Patients with BRCA1, BRCA2, and ATM Mutations

Posted by Maha H. Hussain, MD, FACP, FASCO | Dec 2019

Maha H. Hussain, MD, FACP, FASCO, and Celestia S. Higano, MD, discuss the PROfound Trial, which demonstrated increased radiographic progression-free survival (rPFS) with the use of olaparib for mCRPC patients displaying the genetic mutations BRCA1, BRCA2, and ATM. Dr. Hussain outlines previous research of genetic mutations in mCRPC that led to this study, the study design and rationale of using two cohorts with specific mutations (BRCA1, BRCA2, and ATM) and non-specific mutations (other genetic alterations), and results that demonstrate promise for gene-targeted therapies in the future.

Clinical Trial: Zytiga, Lynparza, + DNA Repair Defects

Posted by Maha H. Hussain, MD, FACP, FASCO | Jul 2019

This interview, “Clinical Trial: Zytiga, Lynparza, + DNA Repair Defects,” is provided...

An Update on the PROSPER Trial: Focusing on Nonmetastatic CRPC

Posted by Maha H. Hussain, MD, FACP, FASCO | Mar 2018

Dr. Maha H.A. Hussain, MBChB, reviews the PROSPER trial, which tested the efficacy and safety of enzalutamide in the setting of nonmetastatic CRPC. Following her summary, she and Dr. E. David Crawford, MD, engage in a question and answer session.